Quick Answer
MapLight Therapeutics, Inc. reported Cash and Equivalents of $46.73 million for fiscal year 2025.
MapLight Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $46.73M | +22.2% |
| 2024 | $38.25M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $64.15M | — | +67.7% |
| December 31, 2024 | $38.25M | — | — |
- MapLight Therapeutics, Inc. showed an increase of +22.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, MapLight Therapeutics, Inc.’s cash and equivalents has grown by 22.2% (from $38.25 million to $46.73 million).
- The most recent figure is from MapLight Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: